Compositions and methods of replication deficient adenoviral vectors for vaccine applications
The invention includes compositions and methods of generating a chimpanzee-derived adenovirus AdC6 or AdC7 vector vaccine comprising a deletion of E1, a deletion of E3 ORF3, ORF4, ORF5, ORF6, and ORF7 and a sequence encoding HIV protein gp140, gp160 or Gag, methods of treating and/or preventing or immunizing against HIV and methods of inducing an effector T cell, memory T cell and B cell immune response in a mammal administered the composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a mammal as well as a protein expression system.
1. A composition comprising a nucleic acid sequence of a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, wherein the early gene E1 is deleted, the ORF3, ORF4, ORF5, ORF6, and ORF7 from the early gene E3 are deleted, and wherein the nucleic acid sequence further comprises a promoter sequence linked to a sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NOs. 1-8.
2. The composition of claim 1 , wherein the promoter is a constitutive promoter.
3. The composition of claim 1 , wherein the promoter is a cytomegalovirus immediate early promoter (CMV).
4. A protein expression system comprising the composition of claim 1 , wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 1-8.
5. A protein expression system comprising the composition of claim 1 , wherein the nucleic acid sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-16.
6. A method of eliciting an immune response in a mammal against a heterologous protein, the method comprising administering to the mammal a composition comprising a nucleic acid sequence of a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the nucleic acidsequence further comprises a promoter sequence linked to a sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NOs. 1-8.
7. A method of treating and/or preventing HIV in a mammal, the method comprising:
(a) administering a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag to a mammal in an amount effective to elicit an immune response in the mammal; and
(b) administering to the mammal at a second subsequent time period a second chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7 that differs from the serotype of the adenovirus vector of (a), comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the second adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag, wherein T memory cells directed against the heterologous protein are reactivated in the mammal.
8. A method of vaccinating a mammal against HIV infection, the method comprising:
(a) administering a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag to a mammal in an amount effective to elicit an immune response in the mammal; and
(b) administering to the mammal at a second subsequent time period a second chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7 that differs from the serotype of the adenovirus vector of (a), comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the second adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag, wherein T memory cells directed against the heterologous protein are reactivated in the mammal.
9. The method of claim 8 , wherein the adenovirus vectors are administered prophylactically to the mammal.
10. The method of claim 8 , wherein the adenovirus vectors are administered therapeutically to the mammal.
11. The method of claim 8 , wherein the adenovirus vectors are administered in combination with an adjuvant.
12. A method of generating an immune response in a mammal, the method comprising the steps of:
(a) administering a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag to a mammal in an amount effective to elicit an immune response in the mammal; and
(b) administering to the mammal at a second subsequent time period, a second chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7 that differs from the serotype of the adenovirus vector of (a), comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the second adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag, wherein T memory cells directed against the heterologous protein are reactivated in the mammal.
13. The method of claim 12 , wherein the adenovirus vector of serotype AdC6 and the adenovirus vector of serotype AdC7 comprise a same or a different HIV heterologous protein selected from the group consisting of gp140, gp160 and Gag.
14. The method of claim 7 , wherein the mammal is a human.
15. The method of claim 7 , further comprising (c) administering to the mammal a heterologous protein selected from the group consisting of gp140, gp145, gp160, and Gag.
16. The method of claim 12 , further comprising (c) administering to the mammal a heterologous protein selected from the group consisting of gp140, gp145, gp160, and Gag.
17. A method of treating and/or preventing HIV in a mammal, the method comprising:
(a) administering a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag to a mammal in an amount effective to elicit an immune response in the mammal; and
(b) administering to the mammal a heterologous protein selected from the group consisting of gp140, gp145, gp160, and Gag at a second, subsequent time period.
18. A method of vaccinating a mammal against HIV infection, the method comprising:
(a) administering a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag to a mammal in an amount effective to elicit an immune response in the mammal; and
(b) administering to the mammal a heterologous protein selected from the group consisting of gp140, gp145, gp160, and Gag at a second, subsequent time period.
19. A method of generating an immune response in a mammal, the method comprising the steps of:
(a) administering a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E 3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene El is deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp 140 , gp 160 and Gag to a mammal in an amount effective to elicit an immune response in the mammal; and
(b) administering to the mammal a protein a heterologous protein selected from the group consisting of gp 140 , gp 145 , gp 160 , and Gag at a second, subsequent time period.
20. A method of treating and/or preventing HIV in a mammal, the method of comprising administering to the mammal a therapeutically effective amount of a composition administering to the mammal a theraeutically effective amount of a composition encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-8.
21. A method of vaccinating a mammal against HIV infection, the method comprising administering to the mammal a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E 3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 6 are deleted, wherein the early gene E 1 is deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag to a mammal in an amount effective to elicit an immune response in the mammal, wherein T memory cells directed against the heterologous protein are reactivated in the mammal, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NOs 1-8.
22. The method of claim 21 , wherein the adenovirus vector is administered prophylactically to the mammal.
23. The method of claim 21 , wherein the adenovirus vector is administered therapeutically to the mammal.
24. The method of claim 12 , wherein the adenovirus vector is administered in combination with an adjuvant.
25. A method of generating an immune response in a mammal, the method comprising the steps of:
(a) administering a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, comprising an early gene E 3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E 1 is deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a first heterologous protein, to a mammal in an amount effective to elicit an immune response in the mammal; and
(b) subsequently administering to the mammal a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7, wherein the early gene E 1 is deleted, the ORF3, ORF4, ORF5, ORF6, and ORF7 from the early gene E 3 are deleted, and wherein the adenovirus vector comprises a promoter sequence linked to a nucleic acid sequence encoding a second heterologous protein, wherein T memory cells directed against the heterologous protein are reactivated in the mammal, wherein the first heterologous protein and the second heterologous protein are the same heterologous protein or different heterologous proteins and are selected from the group consisting of gp140, gp145, gp160, and Gag.
26. The method of claim 25 , wherein the first heterologous protein and the second heterologous protein are the same heterologous protein.
27. The method of claim 25 , wherein the first heterologous protein and the second heterologous protein are different heterlogous proteins.
28. The method of claim 20 , wherein the mammal is a human.
29. The method of claim 21 , wherein the mammal is a human.
30. The method of claim 25 , wherein the mammal is a human.